Magdalena Zaniewska

Dr. Magdalena Zaniewska

Maj Institute of Pharmacology Polish Academy of Sciences, Smetna Street 12, 31-343 Krakow
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2013 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
KWKarolina Wydra
Karolina Wydra
KGKrystyna Golembiowska
Krystyna Golembiowska
Magdalena ZaniewskaMagdalena Zaniewska
Magdalena Zaniewska
KKKatarzyna Kamińska
Katarzyna Kamińska
LUCA FERRAROLUCA FERRARO
LUCA FERRARO
MFMałgorzata Filip
Małgorzata Filip

1 January 2012 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MFMałgorzata Filip
Małgorzata Filip
Magdalena ZaniewskaMagdalena Zaniewska
Magdalena Zaniewska
MFM. Frankowska
M. Frankowska
KWK. Wydra
K. Wydra
KFKjell Fuxe
Kjell Fuxe
Drug addiction is a serious brain disorder with somatic, psychological, psychiatric, socio-economic and legal implications in the developed world. Illegal (e.g., psychostimulants, opioids, cannabinoids) and legal (alcohol, nicotine) drugs of abuse create a complex behavioral pattern composed of drug intake, withdrawal, seeking and relapse. One of the hallmarks of drugs that are abused by humans is that they have different mechanisms of action to increase dopamine (DA) neurotransmission within the mesolimbic circuitry of the brain and indirectly activate DA receptors. Among the DA receptors, D2 receptors are linked to drug abuse and addiction because their function has been proven to be correlated with drug reinforcement and relapses. The recognition that D2 receptors exist not only as homomers but also can form heteromers, such as with the adenosine (A)2A receptor, that are pharmacologically and functionally distinct from their constituent receptors, has significantly expanded the range of potential drug targets and provided new avenues for drug design in the search for novel drug addiction therapies. The aim of this review is to bring current focus on A2A receptors, their physiology and pharmacology in the central nervous system, and to discuss the therapeutic relevance of these receptors to drug addiction. We concentrate on the contribution of A2A receptors to the effects of different classes of drugs of abuse examined in preclinical behavioral experiments carried out with pharmacological and genetic tools. The consequences of chronic drug treatment on A2A receptor-assigned functions in preclinical studies are also presented. Finally, the neurochemical mechanism of the interaction between A2A receptors and drugs of abuse in the context of the heteromeric A2A-D2 receptor complex is discussed. Taken together, a significant amount of experimental analyses provide evidence that targeting A2A receptors may offer innovative translational strategies for combating drug addiction.

1 March 2006 in Brain Research
Verified
Journal Article
Closed access
MFMałgorzata Filip
Małgorzata Filip
MFMałgorzata Frankowska
Małgorzata Frankowska
Magdalena ZaniewskaMagdalena Zaniewska
Magdalena Zaniewska
EPEdmund Przegaliński
Edmund Przegaliński
CMChrista Müller
Christa Müller
KFKjell Fuxe
Kjell Fuxe

1 June 2010 in Neuropharmacology
Verified
Journal Article
Closed access
Magdalena ZaniewskaMagdalena Zaniewska
Magdalena Zaniewska
AMAndrew C. McCreary
Andrew C. McCreary
KWKarolina Wydra
Karolina Wydra
MFMałgorzata Filip
Małgorzata Filip

1 July 2006 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Magdalena ZaniewskaMagdalena Zaniewska
Magdalena Zaniewska
AMAndrew C. McCreary
Andrew C. McCreary
EPEdmund Przegaliński
Edmund Przegaliński
MFMałgorzata Filip
Małgorzata Filip

28 February 2017 in Neurotoxicity Research
Verified
Journal Article
Open access
PDF file
ISIrena Smaga
Irena Smaga
JJJoanna Jastrzębska
Joanna Jastrzębska
Magdalena ZaniewskaMagdalena Zaniewska
Magdalena Zaniewska
BBBeata Bystrowska
Beata Bystrowska
DGDawid Gawliński
Dawid Gawliński
MFMałgorzata Filip
Małgorzata Filip
A growing body of evidence implicates the endocannabinoid (eCB) system in the pathophysiology of depression. The aim of this study was to investigate the influence of changes in the eCB system, such as levels of neuromodulators, eCB synthesizing and degrading enzymes, and cannabinoid (CB) receptors, in different brain structures in animal models of depression using behavioral and biochemical analyses. Both models used, i.e., bulbectomized (OBX) and Wistar Kyoto (WKY) rats, were characterized at the behavioral level by increased immobility time. In the OBX rats, anandamide (AEA) levels were decreased in the prefrontal cortex, hippocampus, and striatum and increased in the nucleus accumbens, while 2-arachidonoylglycerol (2-AG) levels were increased in the prefrontal cortex and decreased in the nucleus accumbens with parallel changes in the expression of eCB metabolizing enzymes in several structures. It was also observed that CB1 receptor expression decreased in the hippocampus, dorsal striatum, and nucleus accumbens, and CB2 receptor expression decreased in the prefrontal cortex and hippocampus. In WKY rats, the levels of eCBs were reduced in the prefrontal cortex (2-AG) and dorsal striatum (AEA) and increased in the prefrontal cortex (AEA) with different changes in the expression of eCB metabolizing enzymes, while the CB1 receptor density was increased in several brain regions. These findings suggest that dysregulation in the eCB system is implicated in the pathogenesis of depression, although neurochemical changes were linked to the particular brain structure and the factor inducing depression (surgical removal of the olfactory bulbs vs. genetic modulation).